Forge Medical, a US developer of solutions for transradial and transpedal haemostasis and manufacturer of the VasoStat haemostasis device, announced today that the company has entered into a commercialisation agreement with Lokai Medical.
Lokai Medical, based in Phoenix, USA, is a specialty distributor of coronary/cardiovascular and interventional devices throughout the USA.
Timothy Clark, CEO of Forge Medical, said: “Transradial and transpedal approaches are becoming increasingly adopted by interventional cardiologists, interventional radiologists and vascular surgeons. These clinicians demand an effective solution for puncture site management with rapid and patent haemostasis and optimal patient comfort. We are pleased to partner with the talented team at Lokai Medical to provide this unique and innovative haemostasis device to ever growing numbers of US clinicians and hospitals.”
Read Clark’s article Lessons on Device innovation on the rocky road to commercialising devices. He is also speaking at the upcoming Charing Cross Symposium (24–28 April, London, UK) in the Innovation Showcase.
